Literature DB >> 10614777

Characterization of a CSF-induced proliferating subpopulation of human peripheral blood monocytes by surface marker expression and cytokine production.

M Finnin1, J A Hamilton, S T Moss.   

Abstract

The phenotype of a subpopulation(s) of human monocytes which has been shown to proliferate in vitro in response to macrophage colony-stimulating factor (M-CSF or CSF-1) and granulocyte-macrophage CSF (GM-CSF) is as yet unknown. To identify this proliferating subpopulation(s) we demonstrated first that DNA synthesis was occurring under culture conditions suitable for flow cytometric evaluation. Flow cytometric analysis of surface antigen expression identified that after 5 days of culture the proliferating subpopulation of monocytes expressed CD14, CD13, CD33, CD11b, CD11c, CD87, HLA-DR, CD45RO, and did not express CD86, CD34, CD80, CD4, CD16, and CD56. In addition, these proliferating monocytes (representing approximately 5% of total monocytes) were shown to produce the proinflammatory cytokines interleukin-6 and tumor necrosis factor alpha in response to lipopolysaccharide stimulation. Further characterization and subsequent isolation of this subpopulation of monocytes may provide new and important information necessary to understand inflammatory diseases such as rheumatoid arthritis, where local proliferation at the site of inflammation may be a key factor contributing to the chronicity of the disease.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10614777     DOI: 10.1002/jlb.66.6.953

Source DB:  PubMed          Journal:  J Leukoc Biol        ISSN: 0741-5400            Impact factor:   4.962


  9 in total

1.  [Prostate cancer screening with a new marker based on circulating blood macrophages?].

Authors:  R Herwig; B Djavan; G Kramer; M A El-Taieb; F Kühhas; M Leers; M Marberger
Journal:  Urologe A       Date:  2007-09       Impact factor: 0.639

2.  Measles virus glycoprotein-pseudotyped lentiviral vectors are highly superior to vesicular stomatitis virus G pseudotypes for genetic modification of monocyte-derived dendritic cells.

Authors:  J-M Humbert; C Frecha; F Amirache Bouafia; T H N'Guyen; S Boni; F-L Cosset; E Verhoeyen; F Halary
Journal:  J Virol       Date:  2012-02-15       Impact factor: 5.103

3.  The quest for a biomarker of circulating osteoclast precursors.

Authors:  Christopher Ritchlin
Journal:  Arthritis Res Ther       Date:  2009-06-17       Impact factor: 5.156

4.  Primary human macrophages serve as vehicles for vaccinia virus replication and dissemination.

Authors:  Daniel Byrd; Nicole Shepherd; Jie Lan; Ningjie Hu; Tohti Amet; Kai Yang; Mona Desai; Qigui Yu
Journal:  J Virol       Date:  2014-04-02       Impact factor: 5.103

5.  Proteasome inhibitor immunotherapy for the epithelial to mesenchymal transition: assessing the A549 lung cancer cell microenvironment and the role of M1, M2a and M2c 'hydrocortisone-polarised' macrophages.

Authors:  Selin Engür-Öztürk; Miriş Dikmen
Journal:  Mol Biol Rep       Date:  2022-03-13       Impact factor: 2.742

6.  Lymphatic endothelial progenitors originate from plastic myeloid cells activated by toll-like receptor-4.

Authors:  Lisa D Volk-Draper; Kelly L Hall; Andrew C Wilber; Sophia Ran
Journal:  PLoS One       Date:  2017-06-09       Impact factor: 3.240

Review 7.  Macrophage Polarization in Leishmaniasis: Broadening Horizons.

Authors:  Fernanda Tomiotto-Pellissier; Bruna Taciane da Silva Bortoleti; João Paulo Assolini; Manoela Daiele Gonçalves; Amanda Cristina Machado Carloto; Milena Menegazzo Miranda-Sapla; Ivete Conchon-Costa; Juliano Bordignon; Wander Rogério Pavanelli
Journal:  Front Immunol       Date:  2018-10-31       Impact factor: 7.561

Review 8.  Cell Sources for Human In vitro Bone Models.

Authors:  Sana Ansari; Keita Ito; Sandra Hofmann
Journal:  Curr Osteoporos Rep       Date:  2021-01-15       Impact factor: 5.096

9.  The proliferative human monocyte subpopulation contains osteoclast precursors.

Authors:  Roya Lari; Peter D Kitchener; John A Hamilton
Journal:  Arthritis Res Ther       Date:  2009-02-17       Impact factor: 5.156

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.